Post-earnings recap
Reported
Wed, May 13, 2026
EPS actual
$1.23
EPS est.
$1.39
EPS surprise
-11.70%
1-day move
+2.78%
Prestige Consumer Healthcare's earnings report showed a significant miss on EPS expectations, which could raise concerns among investors. However, the stock reacted positively, increasing by 2.78%, possibly due to market factors unrelated to earnings. The lack of revenue data and management commentary leaves some uncertainty about the company's performance outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.23 | $1.39 | -11.70% |
| Revenue | N/A | $295M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Prestige Consumer Healthcare Inc. (PBH) operates in the health care sector, focusing on over-the-counter pharmaceuticals and consumer health products. With a market cap of $2 billion, the company plays a significant role in the consumer health market, which has seen increased demand due to heightened health awareness among consumers.
Last quarter
In Q3-2026, Prestige reported an EPS of $1.14, slightly below the estimate of $1.16, resulting in a stock decline of 2.21% the following day. The company has faced challenges in meeting earnings expectations recently.
EPS beat streak
1Q
EPS beat rate
63%
Avg EPS surprise
+0.71%
Avg 1-day reaction
+2.58%
Analysts expect Prestige to report an EPS of $1.39 and revenue of $295 million for Q4-2026, reflecting cautious optimism as the company seeks to rebound from previous misses.
Bull case
If Prestige can exceed EPS expectations, it may indicate a strong recovery in sales and improved operational efficiency, potentially driving the stock higher.
Bear case
Conversely, if the company fails to meet expectations again, it could raise concerns about its growth trajectory and market competitiveness, leading to further stock declines.
Key metrics to watch
EPS
$1.39Earnings per share is a key indicator of the company's profitability and performance relative to expectations.
Revenue
$295MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $1.39?
A beat on EPS could signal a turnaround in the company's performance and boost investor confidence.
Q2
What factors contributed to the revenue forecast of $295 million?
Understanding the drivers behind revenue expectations will help assess the company's market position and growth potential.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.4%
Why consensus could be wrong
The consensus may be underestimating the potential for a strong rebound in sales, as recent product launches could drive unexpected revenue growth.
Supporting evidence
The stock has shown resilience in past quarters, often bouncing back after initial misses.
Options pricing suggests a larger move than historical averages, indicating heightened expectations.
Recent trends in consumer health spending may not be fully reflected in analyst forecasts.
Key risk
If revenue exceeds $300 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The upcoming earnings report is critical as it follows a series of misses, and investors are keen to see if the company can regain momentum.
Bull confirmed if
An EPS of $1.40 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $1.38 would support the bear case, raising concerns about the company's ability to grow.
What the market is pricing for the move.
Implied Move
±14.43%
Historical Avg
±5.6%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.
Options are pricing ±14.4% while PBH has averaged ±5.6% over the last 8 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
42.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 2 of 3 (67%)
This setup has occurred 30 times across Health Care in the last 2 years. 2 of 3 (67%) reversed within 5 days — this setup typically fades. The average absolute 1-day move is 3.7%, with a raw directional average of -2.2% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
116.58%
of float
Insider
1.41%
of float
Holders
435
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
7,831,333 sh · $372.5M
16.53%
6.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Prestige beats expectations, history suggests a potential stock increase of around 5.17%, confirming a recovery narrative.
In line / cautious
If results are in line with expectations, the stock may react moderately, reflecting ongoing caution among investors.
Miss
A miss could lead to a decline of approximately 3.63%, further eroding investor confidence in the company's growth prospects.
The lines on the call that would change the story.
Ariel Investments, LLC
4,868,711 sh · $231.6M
10.28%
13.9%
Vanguard Portfolio Management LLC
2,825,340 sh · $134.4M
5.96%
0.8%
Dimensional Fund Advisors LP
2,661,291 sh · $126.6M
5.62%
-0.4%
Fuller & Thaler Asset Management Inc.
2,331,821 sh · $110.9M
4.92%
100.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.